Tiziana Life Sciences Announces Purchase of Common Shares by Chairman and Acting CEO

Rhea-AI Summary

Tiziana Life Sciences Ltd. (Nasdaq: TLSA) announced that Chairman and Acting CEO Gabriele Cerrone acquired 25,000 shares at $0.58 each, increasing his total ownership to 38,640,737 shares. The company focuses on developing immunomodulation therapies, particularly its lead candidate, intranasal foralumab, a fully human anti-CD3 monoclonal antibody. Phase 2 trials for foralumab are anticipated to commence in Q3 2023, targeting patients with non-active Secondary Progressive Multiple Sclerosis (SPMS). This innovative treatment route aims to enhance efficacy and tolerability compared to traditional IV delivery methods.

Positive

• Chairman purchased 25,000 shares, indicating confidence in the company.
• Intranasal foralumab expected to start Phase 2 trials in Q3 2023, which could bolster future growth.
• Innovative delivery methods may improve efficacy and safety of therapies.

Negative

• None.

NEW YORK, March 17, 2023 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announces that it has been notified that Gabriele Cerrone, its Chairman and Acting Chief Executive Officer, purchased 25,000 common shares at $0.58 per share, bringing his total holding to 38,640,737 common shares.

About Foralumab
Activated T cells play an important role in the inflammatory process. Foralumab, the only fully human anti-CD3 monoclonal antibody (mAb), binds to the T cell receptor, dampens inflammation by modulating T cell function, thereby suppressing effector features in multiple immune cell subsets, an effect demonstrated in patients with COVID and with multiple sclerosis, as well as in healthy normal subjects. Intranasal foralumab Phase 2 trials are expected to start in Q3 2023 in patients with non-active SPMS. Immunomodulation by nasal anti-CD3 mAb represents a novel avenue for treatment of inflammatory human diseases.¹

About Tiziana Life Sciences
Tiziana Life Sciences is a clinical-stage biopharmaceutical company developing breakthrough therapies using transformational drug delivery technologies to enable alternative routes of immunotherapy. Tiziana’s innovative nasal, oral and inhalation approaches in development have the potential to provide an improvement in efficacy as well as safety and tolerability compared to intravenous (IV) delivery. Tiziana’s lead candidate, intranasal foralumab, the only fully human anti-CD3 mAb, has demonstrated a favorable safety profile and clinical response in patients in studies to date. Tiziana’s technology for alternative routes of immunotherapy has been patented with several applications pending and is expected to allow for broad pipeline applications.

For further inquiries:

Tiziana Life Sciences Ltd
Paul Spencer, Business Development and Investor Relations
+44 (0) 207 495 2379
info@tizianalifesciences.com

Investors:
Irina Koffler
LifeSci Advisors, LLC
646.970.4681
ikoffler@lifesciadvisors.com 

___________________________
¹ https://www.pnas.org/doi/10.1073/pnas.2220272120

FAQ

What recent share purchase did Tiziana Life Sciences' Chairman make?

Gabriele Cerrone purchased 25,000 common shares at $0.58 each, raising his total to 38,640,737 shares.

What is intranasal foralumab?

Intranasal foralumab is a fully human anti-CD3 monoclonal antibody being developed by Tiziana for immunomodulation.

When will the Phase 2 trials for foralumab start?

Phase 2 trials for intranasal foralumab are expected to begin in Q3 2023.

What potential benefits does Tiziana’s drug delivery technology offer?

Tiziana’s technology aims to enhance efficacy and safety compared to traditional intravenous delivery methods.